BioLife Solutions stock was downgraded to a 'Hold' rating with a $31 price target by Lake Street amid its proposed $1.5 billion acquisition by Repligen Corporation. The deal, a cash-and-stock offer, is under legal scrutiny by Halper Sadeh LLC, which questions whether the terms fairly benefit BioLife shareholders. GuruFocus estimates BioLife's fair value at $28.93, higher than the acquisition offer, raising concerns about the board's fiduciary duties. Investors should watch for developments in the shareholder investigation and final deal approval.
The global Botulinum Toxin in Urology Market is projected to grow from approximately USD 1.16 billion in 2026 to USD 1.98 billion by 2035, at a CAGR of 6.08%. Growth is fueled by increasing prevalence of urological disorders like overactive bladder, ...
Altius Minerals Corporation sees a price target increase from C$51 to C$54 by Bank of Montreal, reflecting optimism despite a 'Market Perform' rating. The company projects record Q2 2026 royalty revenue of about $30 million, up from $12.7 million a y...
Badger Meter reported Q2 2026 earnings per share of $1.02 and revenue of $222.32 million, both slightly above analyst expectations. Although revenue declined 7% year-over-year, the company saw a 9% sequential increase in base sales due to new advance...
The global robotic endoscopy devices market is projected to grow at a compound annual growth rate (CAGR) of about 10% from 2026 to 2034, reaching an estimated value of $6.5 billion by 2034. This growth is fueled by increasing demand for minimally inv...
The Sterling, a new luxury cocktail lounge inspired by 1920s elegance, is launching an exclusive investor event on August 1, 2026, in Orlando's Lake Nona. Created by award-winning Hollywood editor Sam Mordenga, the concept blends architecture, live e...
